Hla-Bb, Dr3 T Cell Impairhent is Completely Restored by in Vitho Treatment with Interleukin-2
- 1 January 1991
- journal article
- research article
- Published by Taylor & Francis in Immunopharmacology and Immunotoxicology
- Vol. 13 (4) , 551-561
Abstract
The activity of recombinant interleukin-2 (rIL-2) on the in vitro lymphocyte proliferative response to phytohemagglutinin mitogen was investigated in healthy HLA-B8,DR3 positive and negative subjects. The response to mitogen, significantly decreased in HLA-B8,DR3 positive subjects, was completely restored by adding rIL-2. Moreover, in HLA-B8,DR3 positive subjects the in vitro treatment with rIL-2 significantly increased the reduced frequency of mitogen responsive T lymphocyte precursors, as assessed by limiting dilution analysis. These data suggest that a decrease in the size of the pool of T cell precursors able to produce IL-2 is responsible for the impairment of T cell function observed in HLA-B8,DR3 positive subjects. Since in autoimmune diseases it is possible to show the same impairment(s) of T cell functions which can be observed in HLA-B8,DR3 positive subjects, these results could be of practical value for the understanding of pathogenetic mechanism(s) of autoimmune diseases and, in case, for therapeutical purposes.Keywords
This publication has 3 references indexed in Scilit:
- Markers of T Lymphocyte Activation in HLA-B8, DR3 Positive IndividualsImmunobiology, 1990
- Mechanism of a lymphocyte abnormality associated with HLA-B8/DR3: role of interleukin-1Clinical and Experimental Immunology, 1990
- Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes.Journal of Experimental Medicine, 1984